Objective: To compare the efficacy and safety of antithrombotic prophylaxis given for 1 week or 4 weeks in patients undergoing laparoscopic surgery for colorectal cancer. Background: Extending antithrombotic prophylaxis beyond 1 week reduces the incidence of venous thromboembolism (VTE) after open abdominal surgery for cancer. Methods: In consecutive patients who underwent laparoscopic surgery for colorectal cancer, complete compression ultrasonography of the lower limbs was performed after 8 ± 2 days of antithrombotic prophylaxis. Patients with no evidence of VTE were randomized to short (heparin withdrawal) or to extended (heparin continued for 3 additional weeks) prophylaxis. Complete compression ultrasonography was repeated at day 28 ± 2 after surgery by investigators blinded to treatment allocation. The primary outcome of the study was the composite of symptomatic and ultrasonography-detected VTE at day 28 ± 2 after surgery. Results: Overall, 301 patients were evaluated for inclusion in the study and 225 were randomized. VTE occurred in 11 of 113 patients randomized to short (9.7%) and in none of the 112 patients randomized to extended heparin prophylaxis (P = 0.001). The incidence of VTE at 3 months was 9.7% and 0.9% in patients randomized to short or to extended heparin prophylaxis, respectively (relative risk reduction: 91%, 95% confidence interval: 30%-99%; P = 0.005). The rate of bleeding was similar in the 2 treatment groups. Two patients died during the study period, 1 in each treatment group. Conclusions: After laparoscopic surgery for colorectal cancer, extended antithrombotic prophylaxis is safe and reduces the risk for VTE as compared with 1-week prophylaxis (NCT01589146). thrombosis (from 22% to 9%), pulmonary embolism (from 2% to 1.3%), 2 fatal pulmonary embolism (from 0.8% to 0.3%), and of allcause mortality (from 4.2% to 3.2%).
thrombosis (from 22% to 9%), pulmonary embolism (from 2% to 1.3%), 2 fatal pulmonary embolism (from 0.8% to 0.3%), and of allcause mortality (from 4.2% to 3.2%). 3, 4 Current guidelines recommend the use of in-hospital antithrombotic prophylaxis after open abdominal surgery for cancer. 1 Antithrombotic prophylaxis extended to 4 weeks after surgery should be considered in patients at high risk for VTE and at low risk for bleeding complications. 5 This recommendation is based on the consistent results of 2 randomized, double-blind studies. 6, 7 Since the 1990s, the laparoscopic approach has been increasingly used in abdominal surgery. The laparoscopic approach was an exclusion criterion in most clinical trials that showed a benefit of antithrombotic prophylaxis after major cancer surgery. The need for extended antithrombotic prophylaxis after laparoscopic surgery for cancer is unclear. [8] [9] [10] [11] [12] We performed a randomized study to compare the efficacy and safety of antithrombotic prophylaxis given for 1 week or 4 weeks in patients undergoing laparoscopic surgery for colorectal cancer.
METHODS

Patients and Study Design
Consecutive patients who had undergone elective laparoscopic surgery for colorectal cancer in 5 hospitals (all in Italy) were considered for inclusion in the study. Patients were excluded in case of age less than 18 years, noncancer surgery, anticipated duration of surgery shorter than 45 minutes, conversion from laparoscopic to open surgery, other indication for anticoagulant treatment, major postsurgery complications leading to reoperation or bleeding before randomization, renal or hepatic failure (creatinine clearance <30 mL/min or a transaminase increase over 3 times upper limit normal), known cerebral metastases, bleeding disorders, intracranial hemorrhage or neurosurgery within the previous 6 months, known hypersensitivity to low-molecular-weight heparin (LMWH), previous heparin-induced thrombocytopenia, pregnancy or lactation, or refusal to participate.
Study Procedures
Study patients received antithrombotic prophylaxis for 8 ± 2 days starting on the evening before surgery. All LMWHs were allowed if given at doses approved for VTE prophylaxis in general surgery. A complete compression ultrasonography of the venous system of the lower limbs was performed at day 8 ± 2 after surgery. 13 Patients with no evidence of VTE were randomized to short (heparin withdrawal) or to extended (heparin continued for 3 additional weeks) prophylaxis in an open fashion. A central randomization (1:1 short vs extended prophylaxis, in permuted blocks of 4, stratified according to study center) was used.
All randomized patients were reevaluated at day 28 ± 2 after surgery by complete compression ultrasonography of the lower limbs by an investigator blinded to treatment allocation. A clinical follow-up visit was planned at 3 months after surgery. Patients were instructed to report to the study center immediately if they had symptoms suggestive of VTE or bleeding complications. Objective testing was required whenever VTE was suspected. In case of death, autopsy was encouraged.
Study Outcomes
The primary efficacy outcome was symptomatic VTE (deep vein thrombosis or pulmonary embolism) or deep vein thrombosis diagnosed at complete compression ultrasonography at day 28 ± 2 from surgery. Computed tomography or pulmonary angiography or ventilation/perfusion lung scanning was done to confirm the clinical suspicion of pulmonary embolism.
The primary safety outcome was major bleeding occurring in the 4 weeks after surgery. Major bleeding was defined according to International Society on Thrombosis and Haemostasis criteria 14 : (1) fatal bleeding and/or (2) bleeding that is symptomatic and occurs in a critical area or organ (such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, in a nonoperated joint, or intramuscular with compartment syndrome, assessed in consultation with the surgeon) and/or (3) extrasurgical site bleeding causing a fall in hemoglobin level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells, with temporal association within 24 to 48 hours to the bleeding and/or (4) surgical site bleeding that requires a second intervention (open, arthroscopic, endovascular) or a hemarthrosis delaying mobilization or wound healing, resulting in prolonged hospitalization or a deep wound infection and/or (5) surgical site bleeding that is unexpected and prolonged and/or sufficiently more to cause hemodynamic instability, as assessed by the surgeon.
Clinically relevant nonmajor bleeding was also reported and was defined as bleeding episodes not meeting criteria for major bleeding but associated with medical intervention. Study outcome events were locally adjudicated by a study investigator unaware of the patients' treatment allocation.
Data Collection
For all patients, the following data were collected: demographic features, medical history, risk factors for VTE, surgery (type, duration, etc), type of anesthesia, length of immobilization, postoperative complications, cancer type and staging, and chemotherapy and radiotherapy. Preoperative immobilization was defined as bed rest for at least 3 days before surgery. Data on study outcome events included signs and/or symptoms of VTE and the cause of death.
Statistical Analysis
With an estimated rate of VTE of 12% in patients randomized to receive prophylaxis for 1 week, we assumed that 248 patients in each group would be necessary to show a 55% reduction by extended antithrombotic prophylaxis (2-sided α 0.05, power 80%). To avoid exposure to a suboptimal prophylaxis, a prespecified interim analysis was planned after 200 patients had completed the 28-day study visit. The following stopping rules were defined a priori: an overall rate of VTE lower than 5% in patients randomized to short antithrombotic prophylaxis, an unequivocal reduction in the rate of VTE in the patients assigned to extended prophylaxis (P < 0.01), a risk for VTE in the extended prophylaxis group that was less than 20% lower than that in the group assigned to short prophylaxis or a rate of major bleeding higher than 5% in the extended group.
For the efficacy analysis, the intention-to-treat population was defined as all randomized patients who received at least 1 dose of the study medication and had 28 ± 2 days of follow-up. Safety analysis included all patients randomly assigned to study treatment who received at least 1 dose of the study medication.
Data were reported as frequencies or means ± SD according to variables. Continuous data were compared with the use of the t test. Categorical data were compared with use of either a χ 2 test or a Fisher exact test. The reported P values are based on 2-sided tests. To assess differences in the rates of VTE between the 2 treatment groups, the relative risk reduction and 95% confidence intervals (CIs) were calculated. Proportional hazards were calculated according to Cox regression statistics. The role of age more than 70 years, sex, stage of malignancy, and duration of surgery as predictor of VTE were evaluated at univariate analysis. Multivariable analysis was constructed from the set of significant (P < 0.05) univariable predictors. This was a no-profit study and the University of Perugia was the sponsor of the study.
The study was performed according to the provisions of the Declaration of Helsinki and good clinical practice. The trial was approved by local ethic committees. Written, informed consent was obtained from all patients or their legal guardians (NCT01589146). All the authors took part in the analysis and interpretation of data and approved the final version of the article.
RESULTS
From March 2010 to July 2012, 301 patients were evaluated and 225 patients were included in the study, 113 patients randomized to short and 112 to extended antithrombotic prophylaxis (Fig. 1) . Causes for exclusion are listed in Figure 1 . All patients received prophylaxis with LMWH from the evening before surgery up to randomization (Table 1) . In this period, 84 patients (37%) received prophylaxis with enoxaparin at a dose of 4000 UI, 41 patients (18%) received dalteparin at the dose of 5000 UI, and 100 patients (45%) received nadroparin at the dose of 2850 UI. The mean duration of LMWH prophylaxis was 7 ± 2.1 days in patients randomized to short prophylaxis and 29 ± 2.2 days in patients randomized to extended prophylaxis. After randomization, 89 patients (79%) allocated to extended prophylaxis received enoxaparin at the dose of 4000 UI and 23 patients (21%) received dalteparin at the dose of 5000 UI. Demographic features, risk factors for VTE, type and stage of cancer, and duration of surgery were similar in the 2 study groups (Table 1) . Bed rest was prolonged for 7 days postsurgery in 1 patient in the short prophylaxis group (due to sepsis) and in 2 patients in the extended prophylaxis group (1 patient due to leakage of the anastomosis and 1 patient due to sepsis).
One patient in each group underwent reintervention between randomization and day 28 ± 2 (1 for intussusception and 1 for pelvic abscess); 1 patient randomized to short prophylaxis underwent open surgery during the 3-month follow-up (for pelvic abscess). 
Venous Thromboembolism
VTE occurred in 11 of 225 patients (4.9%, 95% CI: 2.8%-8.5%) from randomization to day 28 ± 2. All these events occurred in patients randomized to short heparin prophylaxis (11 of 113; 9.7%, 95% CI: 5.5%-16.6%); no episode occurred in patients randomized to extended heparin prophylaxis (95% CI: 0%-3.3%) (P = 0.001). The study was interrupted after the results of the interim analysis were available and showed a reduction in the rate of VTE in patients assigned to extended heparin prophylaxis (P < 0.01).
VTE was proximal or symptomatic deep vein thrombosis in 2 patients, both presenting with signs and symptoms suggestive of VTE before the scheduled day 28 ± 2 examination ( Table 2 ). The remaining 9 venous thromboembolic events were asymptomatic distal deep vein thrombosis. No episode of pulmonary embolism was observed.
During the 3-month follow-up period, VTE was suspected in 1 patient randomized to extended prophylaxis and in none of those randomized to short prophylaxis. Deep vein thrombosis was confirmed in this patient by complete compression ultrasonography. The overall 3-month incidence of VTE was 5.3% (12 events out of 225 patients; 95% CI: 3.1%-9.1%) and, in particular, 9.7% (11 events out of 113 patients; 95% CI: 5.5%-16.6%) in patients randomized to short heparin prophylaxis and 0.9% (1 out of 112; 95% CI: 0.2%-4.9%) in patients randomized to extended heparin prophylaxis (relative risk reduction: 91%, 95% CI: 30%-99%; P = 0.005). None of the patients complained for signs or symptoms suggestive of pulmonary embolism during the 3-month follow-up. The time course of VTE is shown in Figure 2 .
At univariable analysis, age more than 70 years was a predictor of VTE (hazard ratio: 3.89, 95% CI: 1.17-12.93; P = 0.02), and advanced cancer (stage IV according to TNM Classification of Malignant Tumours [TNM]) was associated with a higher but not statistically significant risk of VTE (hazard ratio: 3.2, 95% CI: 0.42-24.90; P = 0.26). Age more than 70 years was confirmed to be an independent predictor of VTE at multivariable analysis (hazard ratio: 3.77, 95% CI: 1.13-12.55; P = 0.03).
Bleeding Complications
One patient randomized to short heparin prophylaxis experienced a major bleeding (intestinal bleeding with a blood loss of >20 g/L and requiring transfusions), and 1 patient randomized to extended prophylaxis experienced a clinically relevant nonmajor bleeding (rectal bleeding requiring heparin withdrawal) from randomization to day Table 2 ). The rate of major or clinically relevant nonmajor bleeding was 0.9% in each group (95% CI: 0.2%-4.8%).
(
Adverse Events
No death occurred during the treatment period. Two patients died during the 3-month follow-up period: 1 (0.9%, 95% CI: 0.2%-4.8%) in the group randomized to short heparin prophylaxis and 1 (0.9%, 95% CI: 0.2%-4.8%) in the group randomized to extended prophylaxis. The cause of death was pancreatitis in 1 patient and cancer progression in the other patient. One patient randomized to short prophylaxis was admitted to the hospital because of a transient ischemic attack 20 days after randomization.
DISCUSSION
This study showed that extended heparin prophylaxis (4 weeks) reduces the rate of VTE in comparison with short prophylaxis (1 week) after laparoscopic surgery for colorectal cancer. This advantage was achieved with no increase in the risk for major or clinically relevant nonmajor bleeding.
Previous studies and meta-analyses showed that, after major abdominal or pelvic surgery, prolonged prophylaxis with LMWH reduces the risk for VTE by about 60% in comparison with prophylaxis limited to hospital stay without increasing the risk for bleeding complications. 15 Patients who had undergone laparoscopic surgery for cancer were not included in these studies.
Laparoscopic surgery for colorectal cancer was firstly introduced in 1991 and since then it is increasingly used. The advantages of laparoscopic surgery over open surgery are less pain and shorter hospital stay, with similar efficacy in the terms of oncology outcomes. However, the need for pneumoperitoneum and reverse Trendelenburg position during laparoscopic surgery could lead to an increased risk of VTE.
Few data are currently available regarding the clinical burden of VTE in laparoscopic surgery for cancer. Two large administrative clinical data sets reported on the incidence of VTE after laparoscopic or open surgery for cancer and noncancer abdominal diseases. 8, 16 These studies reported a significantly higher incidence of perioperative VTE after conventional than after laparoscopic surgery. Among patients who had undergone laparoscopic abdominal surgery, higher rates of VTE were found in colorectal cancer than in benign diseases. 17 Four studies evaluated the incidence of postoperative VTE after laparoscopic surgery for colorectal cancer. [9] [10] [11] [12] Across these studies, the incidence of ultrasonography-detected deep vein thrombosis varied from 0% to 50%. 9, [10] [11] [12] Recommendations for antithrombotic prophylaxis after laparoscopic surgery are different in the currently available international guidelines. The Society of American Gastrointestinal and Endoscopic Surgeons recommends the same regimens of antithrombotic prophylaxis for equivalent open or laparoscopic operations; the European Association for Endoscopic Surgery recommends intraoperative intermittent pneumatic compression of the lower extremities for all prolonged laparoscopic procedures. 18, 19 The Antithrombotic Conference of the American College of Chest Physicians recommends to tailor antithrombotic prophylaxis on the duration of surgery and additional risk factors for VTE rather than on the surgical approach (conventional vs laparoscopic). 1 In our study, the incidence of VTE, either symptomatic or ultrasonography-detected, was 5.3% at 3 months after surgery, which is higher than those previously described in administrative data sets. However, the selection of a high-risk population (cancer patients), the prospective design, and the use of systematic ultrasound screening could account for this increased incidence. The rates of VTE found in our study are consistent with those of previous studies after conventional surgery for cancer. 6 In our study, the incidence of bleeding events was low and similar in patients randomized to short and extended heparin prophylaxis. The incidence of death was low and similar in the 2 treatment groups. No death was deemed to be due to pulmonary embolism or bleeding.
Advanced age was an independent predictor of VTE. Cancer stage IV showed a trend in predicting VTE; the association was not significant probably due to limited number of patients. Advanced age and cancer stage may be important in identifying high-risk patients.
This study has several limitations. This was a study with an open design; however, randomization was central and the operator who performed ultrasonography was blinded to treatment assignment. The suboptimal sensitivity of ultrasonography as screening test for deep vein thrombosis could have underestimated the event rates. However, only 1 patient had a confirmed symptomatic venous thrombosis in the 3-month follow-up. An additional limitation of the study was that patients received different types of LMWH for prophylaxis of VTE. All types and doses of LMWH used in this study were validated in the extended prophylaxis of VTE after major orthopedic surgery.
